---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006385"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:45:17.268700+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corbus Q4 net loss $10.9M; COO Craig Millian departing; CRB-701 ADC licensed from CSPC

## Summary
- Net loss for Q4 2022 was $10.9M ($2.61/diluted share); FY2022 net loss $42.3M ($10.15/diluted share).
- Cash and investments of $59.2M as of Dec 31, 2022, expected to fund operations through Q2 2024.
- COO Craig Millian resigned effective April 14, 2023 to pursue other opportunities.
- Licensed CRB-701 (Nectin-4 ADC) from CSPC; Phase 1 dose escalation ongoing in China for advanced solid tumors.
- CRB-601 (anti-αvβ8 mAb) IND submission scheduled for H2 2023; first patient expected by end of 2023.

## SEC filing metadata
- accession: 0000950170-23-006385
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/0000950170-23-006385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/crbp-20230303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006385
- JSON: https://secwatch.observer/filing/0000950170-23-006385.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006385.txt

## Key facts
- Earnings Releases
  Corbus Pharmaceuticals Holdings, Inc. reported the three months ended December 31, 2022 results: net income a net loss of approximately $10.9 million, EPS a net loss per diluted share of $2.61.
  - Period: the three months ended December 31, 2022
  - Net income: a net loss of approximately $10.9 million
  - EPS: a net loss per diluted share of $2.61
  - Result: reported results
  source text: The Company reported a net loss of approximately $10.9 million, or a net loss per diluted share of $2.61, for the three months ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/0000950170-23-006385-index.htm
- Earnings Releases
  Corbus Pharmaceuticals Holdings, Inc. reported the year ended December 31, 2022 results: net income a net loss of approximately $42.3 million, EPS a net loss per diluted share of $10.15.
  - Period: the year ended December 31, 2022
  - Net income: a net loss of approximately $42.3 million
  - EPS: a net loss per diluted share of $10.15
  - Result: reported results
  source text: For the year ended December 31, 2022, the Company reported a net loss of approximately $42.3 million, or a net loss per diluted share of $10.15
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/0000950170-23-006385-index.htm
- Executive change
  Craig Millian resigned as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc..
  - Action: resigned
  - Role: Chief Operating Officer
  source text: On March 3, 2023, Craig Millian, Chief Operating Officer of the Company, submitted a notice of resignation to the Company to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/0000950170-23-006385-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.